HC sets aside cap on condom prices

Image
Press Trust of India New Delhi
Last Updated : Jul 10 2015 | 4:22 PM IST
Delhi High Court today set aside the government's decision to cap condom prices by including it in the Drug Price Control Order (DPCO), saying the pharma pricing authority's orders on the issue were "illegal and unsustainable".
A bench of Chief Justice G Rohini and Justice Rajiv Sahai Endlaw set aside the November 4, 2013 and July 10, 2014 orders of National Pharmaceutical Pricing Authority (NPPA) by which a ceiling was put on the prices of condoms.
"The orders of NPPA dated November 5, 2013, and July 10, 2014, are illegal and unsustainable. In the result both the said orders are hereby set aside," the court said.
The court's verdict came on the plea of two pharma firms, Reckitt Benckiser and J K Ansell Ltd (JKAL), which had contended that their products were 'devices' and not 'medicines' and thus would not fall under the DPCO and hence, no cap can be put on the prices.
The firms had claimed that their products are luxury products "meant for pleasure" and sought clarification on whether the current ceiling would apply to only utility condoms and whether NPPA was proposing to fix a separate cap on "pleasure condoms".
In its petition, the pharma firms had argued that the low ceiling price would force bigger companies to stop production, which in turn would have a negative effect on population control measures.
The government, however, was of the view that since condoms help to prevent diseases, they come under the classification of 'medicines' and hence, their prices can be controlled.
It was also of the view that if luxury condoms were removed from the DPCO, then the manufacturers would flood the market with their expensive varieties and make their lesser priced contraceptives scarce.
The government also maintained that since condoms were currently in the national list of essential medicines, there could be no gradations like luxury and ordinary, where drugs are concerned.
Earlier, the court had queried as to what was the issue if consumers were willing to pay for premium or luxury male contraceptives.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 10 2015 | 4:22 PM IST

Next Story